Company intelligence / Profile preview
FibroNox
Tucson, Arizona, United Statesfibronox.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
FibroNox has demonstrated robust efficacy in preclinical studies for both halting fibrosis and reducing established fibrosis. Their small-molecule treatments have shown effectiveness at significantly lower dosing with inhaled delivery compared to oral delivery in pre-clinical studies[1][5].
- Therapeutic areas
- PulmonologyOther
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on FibroNox.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FibroNox.